×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
MediLink and Roche partner on cancer drug development
Pharmaceutical Technology
MediLink Therapeutics has signed a global partnership and licence deal with Roche to develop YL211 for solid tumours.
4 months ago
Bear market strikes again: 4D Pharma sinks into administration as creditor calls in loans
Fierce Biotech
4D Pharma has gone into administration after failing to secure a loan to help ride out the “difficult” market conditions.
22 months ago
Irritable Bowel Syndrome Market to Exhibit Growth at a CAGR of 9.3% During the Study Period (2019-2032), Estimates ...
PR Newswire
PRNewswire/ -- DelveInsight's Irritable Bowel Syndrome Market Insights report includes a comprehensive understanding of current treatment...
9 months ago
CJ Bioscience Secures World's Largest Microbiome Drug Pipeline
Businesskorea
CJ Bioscience announced on July 25 that it has confirmed a total of 15 microbiome drug pipelines, setting the record for the highest number...
9 months ago
CJ Bioscience conducts paid-in capital increase of $50 mn
KED Global
South Korea's CJ Bioscience Inc., a pharmaceutical company specializing in intestinal microorganisms called microbiomes, will conduct a...
11 months ago
4D Pharma reveals progress in phase 2 trial of live biotherapeutic candidate in bladder cancer
biopharma-reporter.com
4D Pharma reveals progress in phase 2 trial of live biotherapeutic candidate in bladder cancer ... The AIM-traded firm was presenting a trial-in-...
23 months ago
Firm Advises 4D pharma on Merger with Longevity Acquisition Corporation and Nasdaq ADS Listing
Wilson Sonsini
On March 22, 2021, 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development of Live Biotherapeutic products (LBPs)—a...
37 months ago
UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome
Labiotech.eu
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut.
54 months ago
4D Pharma Begins Phase II COVID-19 Study
Contract Pharma
MRx-4DP0004, an immunomodulatory therapy, has shown potential to down-regulate hyper-inflammatory response while maintaining anti-viral...
48 months ago
4D Pharma and Merck Team to Develop Microbiome-based Vaccines
BioSpace
Under the terms of the deal, 4D will use its proprietary MicroRx platform with Merck's expertise in novel vaccine development and...
54 months ago